Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Protalix BioTherapeutics, Inc. | plx-20201231xex32d2.htm |
| EX-32.1 - EX-32.1 - Protalix BioTherapeutics, Inc. | plx-20201231xex32d1.htm |
| EX-31.2 - EX-31.2 - Protalix BioTherapeutics, Inc. | plx-20201231xex31d2.htm |
| EX-31.1 - EX-31.1 - Protalix BioTherapeutics, Inc. | plx-20201231xex31d1.htm |
| 10-K - 10-K - Protalix BioTherapeutics, Inc. | plx-20201231x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-230604 and 333-237736) and on Form S-8 (No. 333-148983, No. 333-182677, No. 333-203960, No. 333-225526 and No. 333-239101) of Protalix BioTherapeutics, Inc. of our report dated March 30, 2021 relating to the financial statements, which appears in this Form 10-K.
/s/ Kesselman & Kesselman |
|
|
Kesselman & Kesselman |
Certified Public Accountants (lsr.) |
A member firm of PricewaterhouseCoopers International Limited |
|
|
Tel-Aviv, Israel |
March 30, 2021 |